NCT03728569TerminatedEarly Phase 1
Skin Barrier Dysfunction and the Role of Skin Barrier Restoration on Cutaneous and Systemic Inflammation in the Aged Population
Conditions
Trial Snapshot
- Phase
- Early Phase 1
- Status
- Terminated
- Sponsor
- University of Michigan
- Enrollment
- 14
- Locations
- 2
- Primary Endpoint
- Change in skin hydration status in aged and young subjects
Study Overview
Brief Summary
The objective of this exploratory study is to gain an understanding of cutaneous and systemic inflammation and how restoration of the skin barrier through the use of moisturizer may restore the skin barrier function and reduce systemic inflammation in elderly humans compared to the young. The exploratory study will consist of three visits per subject. Subjects will be instructed to apply a moisturizer (Vanicream Moisturizing Skin Cream) over the entire skin surface from the neck down twice daily for up to 30 days.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Aged group (>70 years old)
- •In good general health
- •Body mass index (BMI) preferably in the healthy range (approximately 25 kg/m2) and no greater than 30 kg/m2
- •Fitzpatrick skin types I-V
- •Disrupted skin barrier defined as transepidermal water loss (TEWL) >5 g/m2/h on the upper arms or >3 g/m2/h on the buttocks
- •Clinical signs of skin dryness as determined by the investigator.
- •No disease states or physical conditions that would impair evaluation of the biopsy sites
- •Signed, written and witnessed informed consent form
- •Willing to comply with study procedures
- •Young group (18-30 years old)
- •Good general health
- •BMI preferably in the healthy range (approximately 25 kg/m2) and no greater than 30 kg/m2
- •Fitzpatrick skin types I-V
- •Disrupted skin barrier defined as transepidermal water loss (TEWL) >5 g/m2/h on the upper arms or >3 g/m2/h on the buttocks
- •Clinical signs of skin dryness as determined by the investigator
- •No disease states or physical conditions that would impair evaluation of the biopsy sites
- •Signed, written and witnessed informed consent form
- •Willing to comply with study procedures
Exclusion Criteria
- •Pregnant or lactating women or women contemplating pregnancy for the duration of the protocol (determined by self-report; if subjects are unsure of their pregnancy status, they will be excluded).
- •Frailty as determined by research study nurse
- •History of inflammatory skin conditions such as psoriasis or atopic dermatitis.
- •History of uncontrolled inflammatory or autoimmune disease.
- •History of keloids or any other condition that would complicate wound healing
- •History of allergic reactions to local lidocaine
- •Frequent nonsteroidal anti-inflammatory drug (NSAID) use (not including low dose aspirin) and unwilling/unable to discontinue NSAIDS for 2 weeks prior to enrollment to the end of the study.
- •Systemic steroids (excluding inhaled steroids for asthma) and unwilling/unable to discontinue systemic steroids for 3 weeks prior to enrollment to the end of the study.
- •Topical corticosteroid use within 2 weeks of enrollment.
- •Topical immunomodulation use such as calcineurin inhibitors within 2 weeks of enrollment
- •Other anti-inflammatory or immunodulatory medications (immunosuppression)
- •Received an experimental drug or used an experimental device 30 days prior to admission to the study.
Outcomes
Primary Outcomes
Change in skin hydration status in aged and young subjects
Time Frame: up to 30 days
Trans-epidermal water loss (TEWL) will be performed on the upper arm and buttocks at Visits 1 and 2. This instrument will measure the amount of water that is lost through the skin. The change in skin hydration status in each subject will be assessed and compared between groups.
Secondary Outcomes
No secondary outcomes reported
Investigators
Gary Fisher
Professor
University of Michigan
Study Sites (2)
Loading locations...
Similar Trials
Completed
Not Applicable
ADRN Barrier/Immunoprofiling Exploratory Pilot StudyDermatitis, AtopicEczemaNon-atopic Healthy ControlsDermatitisNCT02115399National Institute of Allergy and Infectious Diseases (NIAID)150
Completed
Phase 1
Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind StudyAtopic DermatitisNCT00863005Moberg Pharma AB
Unknown
Not Applicable
Detection of Skin Epithelial Barrier in Patients With Allergic Skin DisordersSkin InflammationAtopic DermatitisNCT03581747Swiss Institute of Allergy and Asthma Research1,000
Completed
Not Applicable
Skin Barrier Biophysical Properties and Clinical Appearance After Moisturizer in Dry SkinXerosisXerosis CutisDry Skin EczemaNCT03093597University of Arizona37
Completed
Not Applicable
Influence on skin barrier function and elasticity by using serumHealthy adult femaleJPRN-UMIN000037755Japan Clinical Trial Association19